BIOTRONIK, a manufacturer of cardiovascular medical devices, is set to introduce a new Lumax 540 VR-T DX single-chamber implantable cardiac defibrillator (ICD) and Linoxsmart S DX cardiac lead system.
BIOTRONIK said the signals coming from the atrial chambers of a patient’s heart can be sensed by the floating atrial dipole of the Linoxsmart S DX ICD lead and are amplified by a modified atrial input stage of the Lumax 540 VR-T DX device.
The Lumax DX system provides atrial electrograms in addition to the standard ventricular ones and allows physician to use recordings of a three-channel IEGM, showing atrial, ventricular and far-field signals to determine the origin of the tachycardia and to increase treatment efficiency.
Lumax 540 VR-T DX can discriminate supraventricular tachycardias (SVTs), atrial fibrillation and atrial flutter with its SMART detection algorithm and reduces the risk.
Charite University Hospital Alexander Schirdewan said the Lumax DX system combined with BIOTRONIK Home Monitoring can avoid the risks by detecting atrial arrhythmias and enables physicians to intervene.
BIOTRONIK Marketing and Sales global vice president Marlou Janssen said combined with their proprietary algorithms, Lumax 540 devices and the advantage of early detection with BIOTRONIK Home Monitoring, they are able to offer physicians the solutions for single-chamber ICD patients.